● Recruiting

The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.

Condition: Metastatic Triple-negative Breast Cancer · Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

PhasePhase 2

Planned participants60

Who can joinFemale, 18 Years to 70 Years

Healthy volunteersNo

About this study

This is a prospective, multicenter, randomized controlled study aimed at evaluating the efficacy and safety of Trop2-ADC monotherapy or immune combination strategy in the treatment of advanced triple-negative breast cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Zhao JL Professor · +86 15920589334 · zhaojianli1988@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;

Guangzhou, Guangdong, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06851299